Transfer: Rohini challenges CAT order in HC

Bengaluru, May 29: Chief Minister B S Yediyurappa and BJP State President Nalin Kumar Kateel will resolve any differences of opinion among party leaders in Karnataka, according to Minister of State for Railways Suresh Angadi

If anybody has any issues, they should get them resolved by talking with Yediyurappa and Kateel. Internal matters, if any, should not be discussed in public, he said.

Angadi told reporters here on Friday that differences of opinion among party leaders have not come to his notice. A section of party leaders assembling for dinner should not be constituted as a meeting of dissidents. BJP has internal democracy and any differences of opinion if exist will be resolved at the party forum.

He added that if MLA Umesh Katti has any issues regarding cabinet berth or regarding assurances given to him by Yediyurappa during the Lok Sabha elections, he should talk with the chief minister.

Everyone in politics has aspirations and it's natural. Those aspiring for the upcoming Rajya Sabha elections should talk with the chief minister or the state president, he said.

Ramesh Katti was former MP and there was nothing wrong in him being aspirant for Rajya Sabha elections, he said.

Angadi said, "Party is supreme. We shall work for the victory of party candidates irrespective of who they were".

A state cabinet meeting was held on Thursday. Many of the MLAs too had been to Bengaluru for constituency-related works. As they had been meeting after a long time, all gathered for dinner, he expressed.

Mangaluru, Jul 19: Palakkad Division of Southern Railway that has jurisdiction over Mangaluru Railway region has established a business development unit (BDU) to cater to the transportation of various sectors, including non-bulk goods traffic, namely, white goods, finished products, manufactured products, agricultural produce and raw material.

In a statement issued here on Sunday said that the BDU’s mandate was to facilitate seamless interaction between the Railways on the one hand and industry, trade representatives and rail freight customers on the other at appropriate zonal or divisional levels. The unit was also expected to help expeditious clearance of their proposals for freight movement.

Palakkad Divisional Railway Manager Pratap Singh Shami established the BDU in line with the similar unit at the zonal level with other divisions of SR too setting up similar units. Palakkad BDU would work under the supervision of Additional DRM-II CT Sakkeer Hussain while Senior Divisional Operations Manager PL Ashok Kumar was its convener with Senior Divisional Commercial Manager Jerin G Anand, Senior Divisional Mechanical Engineer KV Sundaresan and Senior Divisional Finance Manager AP Sivachandrar were its members.

The United States of America has bought almost the entire world's supply of remdesivir, one of just two drugs proven to treat COVID-19. 

“President Trump has struck an amazing deal to ensure Americans have access to the first authorised therapeutic for Covid-19,” said the US health and human services secretary, Alex Azar. 

“To the extent possible, we want to ensure that any American patient who needs remdesivir can get it. The Trump administration is doing everything in our power to learn more about life-saving therapeutics for Covid-19 and secure access to these options for the American people.”

The announcement implies that no other country in the world will be able to buy remdesivir for next three months at least.

The anti-viral drug patented by the US-based Gilead biotech firm is the only one approved by the European Medicines Agency (EMA) to treat patients with the novel coronavirus.

The Trump administration has already shown that it is prepared to outbid and outmanoeuvre all other countries to secure the medical supplies it needs for the US.

“They’ve got access to most of the drug supply [of remdesivir], so there’s nothing for Europe,” said Dr Andrew Hill, senior visiting research fellow at Liverpool University.

Remdesivir, the first drug approved by licensing authorities in the US to treat Covid-19, is made by Gilead and has been shown to help people recover faster from the disease. 

The first 140,000 doses, supplied to drug trials around the world, have been used up. The Trump administration has now bought more than 500,000 doses, which is all of Gilead’s production for July and 90% of August and September.